.jpg?format=webp&width=780)
The study aimed to determine the safety profile of oral phosphodiesterase type 5 inhibitors, focusing on priapism and malignant melanoma. The researchers analyzed individual case safety reports for these drugs from the World Health Organization global database and compared the results to safety data from Food and Drug Administration trials. The study found that priapism was a significant adverse drug reaction for sildenafil, tadalafil, and vardenafil. Additionally, there appears to be a relationship between phosphodiesterase type 5 inhibitor use and malignant melanoma. Further clinical study is needed to determine the clinical risk associated with these findings.
Like
Save
Share